94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Rita Spathis1Deeva Robles Kuriplach1Sabrina Narvesen1Matthew Eybs1Karen Huang1Steven Torres1Madison King1Elizabeth Bagley1
Pia Elustondo2Michael W. Lawlor3Kanneboyina Nagaraju1
Melissa Morales1*- 1Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University, Binghamton, NY, United States
- 2AGADA Biosciences, Halifax, NS, Canada
- 3Department of Pathology & Laboratory Medicine, Medical College of Wisconsin and Diverge Translational Science Laboratory, Milwaukee, WI, United States
A Corrigendum on
Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis
by Spathis R, Kuriplach DR, Narvesen S, Eybs M, Huang K, Torres S, King M, Bagley E, Elustondo P, Lawlor MW, Nagaraju K and Morales M (2025) Front. Immunol. 16:1527840. doi: 10.3389/fimmu.2025.1527840
In the published article, there was an error in the Funding statement. The funder “Duchenne UK” was erroneously excluded. The correct Funding statement appears below.
“The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The authors would like to thank the Parent Project Muscular Dystrophy (PPMD) and Duchenne UK for funding this work.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: AAV9, mdx, Duchenne muscular dystrophy, DMD, gene therapy, immune response, TLR, complement
Citation: Spathis R, Kuriplach DR, Narvesen S, Eybs M, Huang K, Torres S, King M, Bagley E, Elustondo P, Lawlor MW, Nagaraju K and Morales M (2025) Corrigendum: Enhancing AAV-microdystrophin gene therapy after repeat dosing by blocking phagocytosis. Front. Immunol. 16:1593193. doi: 10.3389/fimmu.2025.1593193
Received: 13 March 2025; Accepted: 14 March 2025;
Published: 21 March 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Spathis, Kuriplach, Narvesen, Eybs, Huang, Torres, King, Bagley, Elustondo, Lawlor, Nagaraju and Morales. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Melissa Morales, bW1vcmFsZXNAYmluZ2hhbXRvbi5lZHU=